EP Lab Digest

#

DIGITAL EDITION

Interactive BONUS content delivered to your email

CLICK HERE TO CONTINUE »

Controversies in Ablation

Live meeting in Berlin, Germany during EUROPACE 09

This activity is sponsored by
St. Jude Medical.





CLINICAL EVENTS CALENDAR

  • Tuesday, March 9, 2010 - 23:00
    2010 ACCA Cardiovascular Administrators’ Leadership Conference
    http://www.aameda.org
  • Thursday, March 11, 2010 - 23:00
    10th Annual Spring Meeting on Cardiovascular Nursing
    http://www.escardio.org/congresses/cardio-nursing-2010/Pages/welcome.aspx
  • Saturday, March 13, 2010 - 23:00
    ACC.10 and i2 Summit 2010
    http://www.acc.org
  • Tuesday, May 4, 2010 - 23:00
    SCAI 33rd Annual Scientific Sessions
    http://www.scai.org

Cordex Receives Special Protocol Assessment Approval from FDA for ATPace™

Cordex Pharma, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the design of pivotal, Phase 2b/3 clinical trials evaluating its lead product ATPace™ as an antiarrhythmic drug for the acute treatment of patients with paroxysmal supraventricular tachycardia (PSVT) under the Special Protocol Assessment (SPA) process.

ATPace™ is a novel stable liquid formulation of adenosine 5’-triphosphate (ATP). It is being developed as a therapeutic and diagnostic drug for the management of patients with cardiac arrhythmias. ATP has been used in Europe for more than five decades as the drug of choice for the acute termination of PSVT. During this extended period of time, formulations of ATP have manifested an excellent safety and efficacy profile.

Cordex intends to initiate prospective, double-blind, placebo-controlled and randomized clinical trials with its lead product ATPace™ in approximately 200 patients aimed at demonstrating clinical safety and efficacy sufficient to support a New Drug Application filing of ATPace™ for the treatment of PSVT in emergency room patients.

“We are very pleased with the FDA’s decision; we believe that data to be obtained in the proposed trials would constitute sufficient evidence to support the marketing approval of ATPace™ for the proposed indication,” commented Amir Pelleg, PhD, Cordex’s President and CSO. “Due to its unique mechanism of action in the heart, which involves a central vagal reflex and adenosine, the product of its rapid degradation, ATPace™ has the potential to be an important advance in the treatment of patients with PSVT,” he added.

All Subscriptions are FREE to qualified cardiology professionals

#

  • Subscribe to:
  • Journal
  • Digital Journal
  • E-News
  • RSS feed

CLICK HERE TO CONTINUE »

Newly Revised and Updated for 2009!




Surgical Site Infection Education


CME Showcase



The Use of Remote Robotic Navigation
in Complex Arrhythmias

Complimentary Accredited Web Archive
This activity is designed for electrophysiologists and EP allied professionals.

Diagnosing Coronary Artery Disease: Advanced Cardiovascular Imaging Solutions

Complimentary accredited web archive
This activity is intended for physicians, nurses, and technologists.



LUMEN 2010 - THE SYMPOSIUM ON OPTIMAL TREATMENTS FOR ACUTE MI

Live Symposium

Date: February 25-27
Location: Loews Miami Beach Hotel
Miami Beach, Florida 33139

REVIEW OUR OTHER
CARDIOLOGY BRANDS

Check out our other resources for healthcare professionals of all specialties.
Heart Rhythm

  • Cath Lab Digest
  • Journal Of Invasive Cardiology
  • Vascular Disease Management